Institute for Cancer Research

Kjetil Taskén
Instiute head

Institute for Cancer Research has since its foundation in 1954 played a central role within the field of cancer research both in Norway and internationally. The Institute has seven research departments and more than 320 employees, master students included. About 70% of the employees and projects are externally funded. Read more

Annual report 2018 (pdf):
Abstract (in Norwegian)
Download in single page format - double page (broad) format

Publication overview

Current news and events

Bridging the gap to proteomics with new high-parameter instruments at the Flow Cytometry Core Facility

Flow Cytometry Core Facility Staff
Flow Cytometry Core Facility Staff

Highly multiplexed analysis of cell suspensions or tissue sections is now available at the Institute of Cancer Research. The Flow Cytometry Core facility has recently installed a 30-parameter fluorescence flow cytometer (FACSSymphony A5) and a 135-channel mass cytometer (Helios) with a state-of-the-art tissue imager (Hyperion). The possibility of interrogating more than 20 fluorescence-markers or more than 50 metal-markers simultaneously in millions of individual cells can unveil new cell types, functions and biomarkers for all research areas. The spatial context of tissue microenvironments across complex cellular phenotypes is empowered by the imaging capability of up to 37 protein, RNA and/or DNA markers simultaneously with 1 µm resolution. You can bring archival FFPE tissue and correlate the mass cytometry imaging with all the other data collected for those patients.

Updated and expanded text Nov 4th:Lung cancer research funded by national clinical research program KLINBEFORSK

Åslaug Helland
Åslaug Helland

Åslaug Helland, head of the Translational studies on solid tumours reserach group at the Department of Cancer Genetics at Oslo University Hospital, receives 14,2 mill NOK from The national programme for clinical therapy research - KLINBEFORSK.
The supported project is entitled "Durvalumab After RadioTherapy – the DART-study". The purpose is to see if Durvalumab and radiation therapy can delay the worsening of disease in patients with non-small cell lung cancer normally treated with sequential chemotherapy followed by radiation therapy.

NB: text expanded on Nov 4th, with more details

Units and subpages

View all subunitsHide all subunits